Regulatory framework for advanced therapy medicinal products in Europe and United States
Iglesias-Lopez, Carolina (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Agustí Escasany, M. Antònia (Maria Antònia) (Hospital Universitari Vall d'Hebron)
Obach, Mercè
Vallano, A. (Servei Català de la Salut)

Data:	2019
Resum:	Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative therapies. The European Union (EU) and the United States (US) are fostering their development. For both regions, ATMPs fall under the regulatory framework of biological products, which determines the legal basis for their development. Sub-classifications of advanced therapies are different between regions; while in EU there are four major groups, i. e. gene therapy, somatic cell therapy, tissue engineered therapies and combined advanced therapies, in US the sub-classification covers two major groups of products, i. e. gene therapy and cellular therapy. The inclusion criteria that define a gene therapy are equivalent in both regions, and the exclusion criteria are directly related to the indications of the product. In the EU, there is a clear differentiation between cell and tissue-based products regarding their classification as advanced therapies or coverage by other legal frameworks, whereas in US there is a broader classification about whether or not these products can be categorized as biologic products. Both in EU and in US, in order to classify a cell or a tissue-based product as an advanced therapy, it must be ensured that the processing of the cells implies a manipulation that alters their biological characteristics, although the term of manipulation in US differentiates between structural and nonstructural cells and tissues. The regulatory terminology used to define ATMPs and their sub-classification reveals some differences between EU and US.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; Article ; Versió publicada
Matèria:	Europe ; United States Food and Drug Administration ; Biological products ; Biological therapy ; Cell- and tissue-based therapy ; Genetic therapy ; Legislation and jurisprudence ; Tissue engineering
Publicat a:	Frontiers in Pharmacology, Vol. 10 Núm. JULY (2019) , p. 921, ISSN 1663-9812

DOI: 10.3389/fphar.2019.00921
PMID: 31543814

14 p, 7.7 MB

El registre apareix a les col·leccions:
Articles > Articles publicats